is retatrutide a triple agonist Retatrutide: The first-in-class investigational receptor redefining Type 2 diabetes therapy Retatrutide vs Tirzepatide: Key Differences

Research suggests that combined GIP and GLP-1 activation produces synergistic rather than merely additive effects on appetite and reward processing

How long will coverage continue

As a new hypoglycemic agent, GLP-1RA enhances insulin sensitivity, reduces body weight and protects the cardiovascular system (91), inhibit the expression and phosphorylation of the mTOR protein (92), promote the apoptosis of endometrial cancer cells, and thus play a potential anticancer role

After the initial month, increase to 2mg for another four weeks

In Phase 3 TRIUMPH-4, about 20.9% of participants at the highest dose reported dysesthesia, which means unusual skin sensitivity or tingling

Sweet, salty, and processed foods overstimulate the sense s and can make it harder for the body to recognise when its had enough